Chemical Namelesinurad
Dosage FormTablet (oral; 200 mg)
Drug ClassInhibitors
CompanyIronwood Pharms Inc
Approval Year2015


  • In combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone.
Last updated on 10/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Zurampic (lesinurad) Prescribing Information2018Ironwood Pharmaceuticals, Inc., Cambridge, MA